Over the years, CRI has contributed significantly to the advancement of cancer research. Some notable achievements include:
Support for the development of checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo), which have revolutionized cancer treatment. Funding early research that led to the development of CAR-T cell therapy, a groundbreaking treatment for certain types of blood cancer. Facilitating the discovery of new biomarkers that can predict patient response to immunotherapy. Promoting the use of personalized medicine approaches to tailor cancer treatment to individual patients.
